Micardis is an antihypertensive drug owned by Boehringer Ingelheim that was first authorized for market use on 10 November, 1998. It contains telmisartan as the active ingredient and is available in tablet form for oral administration.
The Micardis generic is expected to be readily available after 06 October, 2022. This release date is because of the expiration of the Micardis patent US8003679, titled 'Use of inhibitors of the renin-angiotensin system', on the same date.
Micardis, due to its active ingredient telmisartan, helps in regulating blood pressure levels. It can also be used in the prevention or treatment of stroke, demonstrating its importance for cardiovascular health.
Micardis has held a total of 1 drug patent, which has now expired. The last patent, 'Use of inhibitors of the renin-angiotensin system' (US8003679), expired on 06 October, 2022, paving the way for the release of Micardis generic. Below are the details of the patent: